Clinical Trials in the UK / NCT07948772
Recruiting
Observational
A Study to Compare the Natural History of Ataxia Telangiectasia (AT) in Children to Healthy Comparators
NCT07948772 · tracked via the Priya Life Science UK tracker
Condition(s) studied
Ataxia Telangiectasia
Study summary
The primary objective of this study is to assess the natural history of AT symptoms and disease progression over time in children aged 1 to 10 years old diagnosed with classic AT.
Eligibility
Inclusion Criteria for the AT Cohort:
* Diagnosis of classic AT based on investigator's assessment of clinical presentation and genotyping.
* If three years to 10 years (\<11 years) old, the primary caregiver has self-reported to the site that the participant with AT can walk approximately 33 feet (10 meters) without support from a helper, and without the use of a walking aid.
* Provision of a valid study participant assent form, as applicable, together with a correctly signed and dated primary caregiver informed consent form.
Inclusion Criteria for the Healthy Comparator Cohort:
* Provision of a valid study participant assent form, as applicable, together with a correctly signed and dated primary caregiver consent form.
Exclusion Criteria for the AT Cohort:
* Participation in a clinical trial of a candidate therapeutic for AT, with last administration of a candidate therapeutic within 30 days or five half-lives (whichever is longer) preceding study baseline (start of data collection). For clarity, ongoing clinical trial participation that does not involve a therapeutic drug is acceptable. An exception to this exclusion is that up to approximately 20 participants receiving levacetylleucine (marketed as AQNEURSA®) in investigational trials, expanded access programs, or as a licensed drug are eligible.
* Previous treatment with a chemotherapeutic agent for cancer.
* Diagnosis of a condition other than AT that, in the opinion of the investigator, would compromise AT symptom measurement or current study participation.
Exclusion Criteria for the Healthy Comparator Cohort:
* Diagnosis of any form of AT.
* Previous treatment with a chemotherapeutic agent for cancer.
* Diagnosis of a condition that, in the opinion of the investigator, would compromise the measurement of movement by wearable devices to serve as healthy comparators to AT participants.
Note: Other protocol-defined inclusion/exclusion criteria may apply.
Primary outcome measure(s)
- AT Cohort: Change From Baseline in AT Neurological Examination Scale Toolkit (A-TNEST) Score — Baseline up to Month 24
- AT Cohort: Change From Baseline in International Cooperative Ataxia Rating Scale (ICARS) Score — Baseline up to Month 24
Trial sites (5)
| Facility | City | Region | Status |
|---|---|---|---|
| USA004 | Los Angeles | California | Not Yet Recruiting |
| USA002 | Baltimore | Maryland | Recruiting |
| USA001 | Boston | Massachusetts | Recruiting |
| USA003 | Houston | Texas | Recruiting |
| GBR001 | Nottingham | United Kingdom | Recruiting |
More Insmed Incorporated trials in the UK
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07948772 on ClinicalTrials.gov ↗ ← All trials in the UK